scholarly article | Q13442814 |
case report | Q2782326 |
P2093 | author name string | Delmar M Lourenço | |
Manoel R A Martins | |||
Ana R P Quidute | |||
Carlos E L Soares | |||
Naiara C B Dantas | |||
P2860 | cites work | Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene | Q28249576 |
Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study | Q30672269 | ||
Giant prolactinomas: clinical management and long-term follow up. | Q30714659 | ||
Prolactinoma manifesting with symptomatic hydrocephalus | Q33630454 | ||
Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). | Q34283436 | ||
The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. | Q34630270 | ||
An Intronic mutation is associated with prolactinoma in a young boy, decreased penetrance in his large family, and variable effects on MEN1 mRNA and protein | Q35072652 | ||
Neurological, psychiatric, ophthalmological, and endocrine complications in giant male prolactinomas: An observational study in Algerian population | Q35197949 | ||
Obstructive hydrocephalus, fifth nerve and hypothalamus involvement: acute presentation of a giant prolactinoma | Q36129666 | ||
MEN1 in children and adolescents: Data from patients of a regional referral center for hereditary endocrine tumors | Q36377417 | ||
Advances in the treatment of prolactinomas | Q36480692 | ||
Clinical presentation and response to therapy in patients with massive prolactin hypersecretion | Q36739645 | ||
Giant prolactinoma and effectiveness of medical management | Q37585823 | ||
Long-Term Natural Course of Pituitary Tumors in Patients With MEN1: Results From the DutchMEN1 Study Group (DMSG). | Q53446846 | ||
Germline mutation landscape of multiple endocrine neoplasia type 1 using full gene next-generation sequencing | Q57492319 | ||
Giant Prolactinoma in Men: Clinical Features and Therapeutic Outcomes | Q58554244 | ||
Giant Prolactinoma of Young Onset: A Clue to Diagnosis of MEN-1 Syndrome | Q58780637 | ||
Mutation analysis of the MEN1 gene in multiple endocrine neoplasia type 1, familial acromegaly and familial isolated hyperparathyroidism | Q58862086 | ||
[Haemorrhagic necrosis of a pituitary adenoma in a case of multiple endocrine neoplasia (author's transl)] | Q72531509 | ||
Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up | Q77114106 | ||
Fluctuating confusional state due to massive macro-prolactinoma resulting in obstructive hydrocephalus | Q77174067 | ||
Novel MEN1 germline mutations in Brazilian families with multiple endocrine neoplasia type 1 | Q80445192 | ||
The impact of clinical and genetic screenings on the management of the multiple endocrine neoplasia type 1 | Q81153715 | ||
Multiple endocrine neoplasia type 1 in Brazil: MEN1 founding mutation, clinical features, and bone mineral density profile | Q81398600 | ||
MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d'étude des Tumeurs Endocrines | Q86546147 | ||
Pituitary adenomas in childhood, adolescence and young adulthood: presentation, management, endocrine and metabolic outcomes | Q37777905 | ||
Giant prolactinomas: the therapeutic approach. | Q38105620 | ||
Giant prolactinomas in women | Q38148633 | ||
Therapy of endocrine disease: the challenges in managing giant prolactinomas | Q38188916 | ||
Assessment of Depression, Anxiety, Quality of Life, and Coping in Long-Standing Multiple Endocrine Neoplasia Type 2 Patients. | Q38918491 | ||
Genetics of multiple endocrine neoplasia type 1 syndrome: what's new and what's old. | Q39129029 | ||
Combined treatment of invasive giant prolactinomas. | Q39356670 | ||
Proptosis as the presenting sign of giant prolactinoma in a prepubertal boy: successful resolution of hydrocephalus by use of medical therapy | Q39504987 | ||
Treatment-resistant pediatric giant prolactinoma and multiple endocrine neoplasia type 1. | Q40730569 | ||
Prolactinomas in children under 14. Clinical presentation and long-term follow-up | Q41221512 | ||
Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients | Q41659209 | ||
Treatment of extensively invasive (giant) prolactinomas with bromocriptine | Q41972064 | ||
Obstructive hydrocephalus and intracranial hypertension caused by a giant macroprolactinoma. Prompt response to medical treatment | Q42484918 | ||
Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients | Q44301609 | ||
Pituitary adenomas in adolescent patients with multiple endocrine neoplasia type 1. | Q44354633 | ||
Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don't forget MEN1 genetic analysis. | Q44476584 | ||
Falsely low serum prolactin in two cases of invasive macroprolactinoma | Q44617301 | ||
Resolution of macroprolactinoma-induced symptomatic hydrocephalus following cabergoline therapy | Q44890954 | ||
Clinical profile and long term follow up of children and adolescents with prolactinomas | Q46301128 | ||
Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men. | Q46869117 | ||
Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up. | Q46969695 | ||
Rapid size reduction of giant prolactinoma following medical treatment | Q47242909 | ||
Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas. | Q47306652 | ||
Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis | Q47425359 | ||
Clinical presentation and outcome of pituitary adenomas in teenagers. | Q48029885 | ||
Giant invasive prolactinomas | Q48186258 | ||
Surgical indication after bromocriptine therapy on giant prolactinomas: effects and limitations of the medical treatment | Q48309678 | ||
Results of treatment of pituitary disease in multiple endocrine neoplasia, type I. | Q48953134 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P921 | main subject | intracranial hypertension | Q18558125 |
prolactinoma | Q954831 | ||
multiple endocrine neoplasia | Q1553018 | ||
multiple endocrine neoplasia type 1 | Q3347154 | ||
P304 | page(s) | 582 | |
P577 | publication date | 2019-08-28 | |
P1433 | published in | Frontiers in Endocrinology | Q27723680 |
P1476 | title | Giant Prolactinoma Causing Hydrocephalus and Intracranial Hypertension as First Manifestations of Multiple Endocrine Neoplasia Type 1 | |
P478 | volume | 10 |